黑料网

Abstract

We derived corneal endothelial cell substitute (CECSi) cells from induced pluripotent stem cells (iPSCs) to treat corneal edema caused by endothelial dysfunction (bullous keratopathy) and developed an effective xeno-free protocol to produce CECSi cells from both clinical grade and research grade iPSCs in order to offer regenerative therapy to CECSi cells framed a hexagonal blended monolayer with Na, K-ATPase alpha 1 subunit articulation, tight intersections, N-cadherin adherence intersection development, and atomic PITX2 articulation, which are qualities of corneal endothelial cells. CECSi cells can be cryopreserved, and defrosted CECSi cell suspensions likewise communicated N-cadherin and ATP1A1. In CECSi cells derived from QHJI01s04, the percentage of residual undifferentiated iPSCs was less than 0.01%. Frozen supplies of Ff-I01s04-and QHJI01s04-determined CECSi cells were moved, defrosted and relocated into a monkey corneal edema model. Compared to the control group, corneal edema was significantly reduced in CECSi-transplanted eyes. A promising strategy for providing bullous keratopathy patients with an iPS-cell-based cell therapy to regain useful vision is demonstrated by our findings.